What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Sell
31
CRBP Quote, Financials, Valuation and Earnings
Last price:
$9.64
Seasonality move
:
47.36%
Day range:
$9.50 - $10.16
52-week range:
$4.64 - $20.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
70.76x
P/B ratio:
1.85x
Volume:
497.7K
Avg. volume:
606.4K
1-year change:
-35.68%
Market cap:
$170.3M
Revenue:
--
EPS (TTM):
-$5.51
Analysts' Opinion
-
Consensus RatingCorbus Pharmaceuticals Holdings, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $42.33, Corbus Pharmaceuticals Holdings, Inc. has an estimated upside of 336.43% from its current price of $9.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $28.00 representing -188.66% downside risk from its current price of $9.70.
Fair Value
-
According to the consensus of 8 analysts, Corbus Pharmaceuticals Holdings, Inc. has 336.43% upside to fair value with a price target of $42.33 per share.
CRBP vs. S&P 500
-
Over the past 5 trading days, Corbus Pharmaceuticals Holdings, Inc. has underperformed the S&P 500 by -4.68% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Corbus Pharmaceuticals Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Corbus Pharmaceuticals Holdings, Inc. revenues have been falling on a year-over-year basis for 11 quarters in a row. In the most recent quarter Corbus Pharmaceuticals Holdings, Inc. reported revenues of --.
Earnings Growth
-
Corbus Pharmaceuticals Holdings, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Corbus Pharmaceuticals Holdings, Inc. reported earnings per share of -$1.90.
Enterprise value:
68M
EV / Invested capital:
0.72x
Price / LTM sales:
70.76x
EV / EBIT:
--
EV / Revenue:
-4.41x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-1.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$446K
Return On Assets:
-48.6%
Net Income Margin (TTM):
--
Return On Equity:
-54.17%
Return On Invested Capital:
-52.96%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1M | -$699.7K | -$446K | -$200K | -$100K | |
| Operating Income | -$45.8M | -$46.2M | -$75.9M | -$15.5M | -$24.4M | |
| EBITDA | -$44.7M | -$45.5M | -$75.5M | -$15.3M | -$24.3M | |
| Diluted EPS | -$11.18 | -$4.70 | -$5.51 | -$1.15 | -$1.90 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $111.7M | $67.3M | $31.2M | $160.9M | $107.6M | |
| Total Assets | $119.6M | $73.8M | $36.3M | $164.2M | $109.5M | |
| Current Liabilities | $17.1M | $17.5M | $31.5M | $11.6M | $17.1M | |
| Total Liabilities | $41.9M | $31.9M | $36M | $13.7M | $17.4M | |
| Total Equity | $77.6M | $41.9M | $311K | $150.5M | $92.1M | |
| Total Debt | $25.9M | $24.3M | $21.5M | $2M | $307K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.5M | -$36.9M | -$59.5M | -$13.9M | -$15.6M | |
| Cash From Investing | $37M | -$119.7M | $64.2M | -$15.4M | $19.6M | |
| Cash From Financing | -$681.5K | $164.7M | $2.8M | $25M | $2.9M | |
| Free Cash Flow | -$37.5M | -$36.9M | -$59.5M | -$13.9M | -$15.6M | |
CRBP
Sector
Market Cap
$170.3M
$29M
Price % of 52-Week High
47.18%
52.89%
Dividend Yield
0%
0%
Shareholder Yield
-0.18%
-1.4%
1-Year Price Total Return
-35.68%
-19%
Beta (5-Year)
2.713
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$10.21
200-day SMA
Buy
Level
$9.45
Bollinger Bands (100)
Sell
Level
8.88 - 14.48
Chaikin Money Flow
Sell
Level
-4.4M
20-day SMA
Sell
Level
$10.94
Relative Strength Index (RSI14)
Sell
Level
34.04
ADX Line
Sell
Level
24.13
Williams %R
Buy
Level
-89.9649
50-day SMA
Sell
Level
$13.27
MACD (12, 26)
Sell
Level
-0.77
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-7.9M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.1828)
Sell
CA Score
(Annual)
Level (-1.7681)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (4.1177)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Stock Forecast FAQ
In the current month, CRBP has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CRBP average analyst price target in the past 3 months is $42.33.
-
Where Will Corbus Pharmaceuticals Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Corbus Pharmaceuticals Holdings, Inc. share price will rise to $42.33 per share over the next 12 months.
-
What Do Analysts Say About Corbus Pharmaceuticals Holdings, Inc.?
Analysts are divided on their view about Corbus Pharmaceuticals Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Corbus Pharmaceuticals Holdings, Inc. is a Sell and believe this share price will drop from its current level to $28.00.
-
What Is Corbus Pharmaceuticals Holdings, Inc.'s Price Target?
The price target for Corbus Pharmaceuticals Holdings, Inc. over the next 1-year time period is forecast to be $42.33 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CRBP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Corbus Pharmaceuticals Holdings, Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRBP?
You can purchase shares of Corbus Pharmaceuticals Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Corbus Pharmaceuticals Holdings, Inc. shares.
-
What Is The Corbus Pharmaceuticals Holdings, Inc. Share Price Today?
Corbus Pharmaceuticals Holdings, Inc. was last trading at $9.64 per share. This represents the most recent stock quote for Corbus Pharmaceuticals Holdings, Inc.. Yesterday, Corbus Pharmaceuticals Holdings, Inc. closed at $9.70 per share.
-
How To Buy Corbus Pharmaceuticals Holdings, Inc. Stock Online?
In order to purchase Corbus Pharmaceuticals Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CRBP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CRBP
Sector
P/E ratio
--
24.19x
PEG ratio
-0.10x
-0.01x
P/B ratio
1.85x
1.84x
Price / LTM sales
70.76x
1.61x
Growth Metrics
CRBP
Sector
Revenue growth
--
4.6%
Earnings growth
-65.32%
10.88%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$1.71
-$0.20
Profitability
CRBP
Sector
Profitability FY 2024
-$600K
$3.5M
Return on invested capital
-52.96%
-31.66%
Return on assets
-48.6%
-27.84%
Return on equity
-54.17%
-37.15%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
11
Balance Sheet
CRBP
Sector
Total cash
$104.3M
$26.8M
Short term investments
$131.9M
$26M
Total assets
$155.9M
$79.7M
Long term debt
$307K
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 4.54% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 2.8% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 3.65% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
